Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
Eligible patients in routine clinical practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with neovascular Age-Related Macula Degeneration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pegaptanib sodium | Drug | pegaptanib sodium intravitreal injection every 6 weeks for 2 years |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline Visual Acuity (VA) at the Final Visit | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. | Baseline, Week 102 or Early Termination (ET) |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline VA at Each Visit | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline VA at Final Visit by Age Group | Participant population (by age group) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by age group (51 to 64 years, greater than or equal to [>=] 65 years) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. |
Inclusion Criteria:
adults with neovascular age-related macula degeneration
Exclusion Criteria:
according to SmPC
Not provided
Not provided
Patients with Age-related Macula degeneration
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Pátrai | Pellopoese | Greece | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Pegaptanib | The usage and dosage recommendations for Macugen (Pegaptanib) was in accordance with the local Summary of Product Characteristics. Participants received Pegaptanib in one eye (designated study eye) while the fellow eye did not receive Pegaptanib. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Pegaptanib | The usage and dosage recommendations for Macugen (Pegaptanib) was in accordance with the local Summary of Product Characteristics. Participants received Pegaptanib in one eye (designated study eye) while the fellow eye did not receive Pegaptanib. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline Visual Acuity (VA) at the Final Visit | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. | Safety Analysis Set (SAS) = Full Analysis Set (FAS): Enrolled participants who received at least 1 dose of Pegaptanib; Number of participants analyzed (N)=participants with evaluable data | Posted | Mean | Standard Deviation | logMAR | Baseline, Week 102 or Early Termination (ET) | eyes | Participants |
|
Not provided
The same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pegaptanib | The usage and dosage recommendations for Macugen (Pegaptanib) was in accordance with the local Summary of Product Characteristics. Participants received Pegaptanib in one eye (designated study eye) while the fellow eye did not receive Pegaptanib. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Intestinal polyp | Gastrointestinal disorders | MedDRA v14.1 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Retinal tear | Eye disorders | MedDRA v14.1 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| C495058 | pegaptanib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, every 6 weeks up to Week 102 |
| Change From Baseline VA at the Final Visit for Participants With Vascular Retinal Pigment Epithelial Detachment (RPED) | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. On the case report form, participants with RPED=those with the "Pigment Epithelial Detachment (PED) present" box ticked at Baseline Visit. | Baseline, Week 102 or ET |
| Change From Baseline NEI-VFQ-25 Overall Composite Score at Each Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general health category. Mean score calculated for each category. Overall composite score=mean of 11 vision-targeted sub categories. Range of composite score=0 to 100 where higher scores represent better functioning. Change: Composite score at Visit X minus composite Score at Baseline, where higher scores represent better functioning. | Baseline, Month 6, 12, 18, and 24 |
| Change From Baseline NEI-VFQ-25 Overall Composite Score at Final Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general health category. Mean score calculated for each category. Overall composite score=mean of 11 vision-targeted sub categories. Range of composite score=0 to 100 where higher scores represent better functioning. Change: Composite score at Visit X minus composite Score at Baseline, where higher scores represent better functioning. | Baseline, Week 102 or ET |
| Change From Baseline NEI-VFQ-25 Sub-scale Scores at Final Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general heath category. Sub-scale score=mean score in a category. Range of sub-scale scores=0 to 100 where higher scores represent better functioning. Change: Sub-scale scores score at Visit X minus sub-scale score at Baseline, where higher scores represent better functioning. | Baseline, Week 102 or ET |
| Baseline, Week 102 or ET |
| Change From Baseline VA at the Final Visit by Age-related Macular Degeneration (AMD) Stage | Participant population (by AMD stage) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by AMD stage (early lesion, late stage lesion, other) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. | Baseline, Week 102 or ET |
| Change From Baseline VA at the Final Visit by Previous Treatment of AMD | Participant population (by previous treatment of AMD) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by previous AMD treatment (yes/no) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. | Baseline, Week 102 or ET |
| Number of Participants for Whom Fluorescein Angiography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (fluorescein angiography) used to monitor AMD treatment. | Every 6 weeks up to Week 102 |
| Number of Participants for Whom Optical Coherence Tomography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (optical coherence tomography) used to monitor AMD treatment. | Every 6 weeks up to Week 102 |
| Number of Participants for Whom Indocyanine Green Angiography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (indocyanine green angiography) used to monitor AMD treatment. | Every 6 weeks up to Week 102 |
| Number of Participants Who Discontinued Treatment Prematurely or Changed Treatment During the Course of the Study | Participants with dose reduction or temporary discontinuation of treatment due to adverse events (AEs). | Baseline through Week 102 |
| Change From Baseline to Final Visit in Intraocular Pressure (IOP) (Before and After Injection) | IOP was measured using either applanation or tonopen before intravitreal injection, reported as pre-dose and post-dose pressure. IOP valid range: 10-21 mmHg. Change: IOP at Visit X minus IOP at Baseline. | Baseline and Week 102 or ET |
| Alexandroupoli |
| Greece |
| Pfizer Investigational Site | Athens | 12462 | Greece |
| Pfizer Investigational Site | Athens | Greece |
| Pfizer Investigational Site | Larissa | Greece |
| Pfizer Investigational Site | Pátrai | Greece |
| Pfizer Investigational Site | Thessaloniki | Greece |
| Pfizer Investigational Site | Xánthi | Greece |
| Other |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) sub-scale scores at baseline | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general heath category. Sub-scale score=mean score in a category. Range of sub-scale scores=0 to 100 where higher scores represent better functioning. n=participants with evaluable data. | Mean | Standard Deviation | scores on a scale |
|
| Procedures used for age-related macular degeneration (AMD) diagnosis | Procedures used in the diagnosis of age-related macular degeneration (AMD) included fluorescein angiography, indocyanine green angiography, and optical coherence tomography. | Number | participants |
|
|
|
|
| Secondary | Change From Baseline VA at Each Visit | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. | SAS; Number of participants analyzed (N)=participants with evaluable data; n=participants with evaluable data at specified time point | Posted | Mean | Standard Deviation | logMAR | Baseline, every 6 weeks up to Week 102 | eyes | Participants |
|
|
|
|
| Secondary | Change From Baseline VA at the Final Visit for Participants With Vascular Retinal Pigment Epithelial Detachment (RPED) | VA measured using Early Treatment Diabetic Retinopathy Study (ETDRS), Snellen chart, or other methods verifying if the participant was able to count fingers, perceive hand motion, or light. VA expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in the logMAR scale represents an improvement in VA. On the case report form, participants with RPED=those with the "Pigment Epithelial Detachment (PED) present" box ticked at Baseline Visit. | SAS subset of participants with RPED at baseline | Posted | Mean | Standard Deviation | logMAR | Baseline, Week 102 or ET | eyes | Participants |
|
|
|
| Secondary | Change From Baseline NEI-VFQ-25 Overall Composite Score at Each Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general health category. Mean score calculated for each category. Overall composite score=mean of 11 vision-targeted sub categories. Range of composite score=0 to 100 where higher scores represent better functioning. Change: Composite score at Visit X minus composite Score at Baseline, where higher scores represent better functioning. | SAS; N=participants with evaluable data; n=participants with evaluable data at specified time point | Posted | Mean | Standard Deviation | scores on a scale | Baseline, Month 6, 12, 18, and 24 |
|
|
|
|
| Secondary | Change From Baseline NEI-VFQ-25 Overall Composite Score at Final Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general health category. Mean score calculated for each category. Overall composite score=mean of 11 vision-targeted sub categories. Range of composite score=0 to 100 where higher scores represent better functioning. Change: Composite score at Visit X minus composite Score at Baseline, where higher scores represent better functioning. | SAS; N=participants with evaluable data | Posted | Mean | Standard Deviation | scores on a scale | Baseline, Week 102 or ET |
|
|
|
|
| Secondary | Change From Baseline NEI-VFQ-25 Sub-scale Scores at Final Visit | Participant-reported 25 item questionnaire. Responses to each question converted to 0-100 score. Questions grouped into 11 vision-targeted categories and 1 general heath category. Sub-scale score=mean score in a category. Range of sub-scale scores=0 to 100 where higher scores represent better functioning. Change: Sub-scale scores score at Visit X minus sub-scale score at Baseline, where higher scores represent better functioning. | SAS; N=participants with evaluable data; n=participants with evaluable data at specified time point and item in questionnaire | Posted | Mean | Standard Deviation | scores on a scale | Baseline, Week 102 or ET |
|
|
|
| Other Pre-specified | Change From Baseline VA at Final Visit by Age Group | Participant population (by age group) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by age group (51 to 64 years, greater than or equal to [>=] 65 years) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. | SAS;N=participants with evaluable data; n=participants with evaluable data at specified time point and age group | Posted | Mean | Standard Deviation | logMAR | Baseline, Week 102 or ET | eyes | Participants |
|
|
|
| Other Pre-specified | Change From Baseline VA at the Final Visit by Age-related Macular Degeneration (AMD) Stage | Participant population (by AMD stage) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by AMD stage (early lesion, late stage lesion, other) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. | SAS subset of participants with AMD; n=participants with evaluable data at specified time point and stage of AMD | Posted | Mean | Standard Deviation | logMAR | Baseline, Week 102 or ET | eyes | Participants |
|
|
|
| Other Pre-specified | Change From Baseline VA at the Final Visit by Previous Treatment of AMD | Participant population (by previous treatment of AMD) that benefited more from Pegaptanib treatment based on change from baseline VA at final visit. VA measured by previous AMD treatment (yes/no) using ETDRS chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if participant able only to count fingers, perceive hand motion, or light. VA expressed as logMAR could range from 0 (representing 20/20 vision) to 1. Change: VA Score at Visit X minus VA Score at Baseline, where a negative change in logMAR scale represents improvement in VA. | SAS subset of participants for who data was collected about previous AMD treatment (yes/no); n=number of participants with evaluable data at specified time point | Posted | Mean | Standard Deviation | scores on a scale | Baseline, Week 102 or ET | eyes | Participants |
|
|
|
| Other Pre-specified | Number of Participants for Whom Fluorescein Angiography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (fluorescein angiography) used to monitor AMD treatment. | SAS | Posted | Number | participants | Every 6 weeks up to Week 102 |
|
|
|
| Other Pre-specified | Number of Participants for Whom Optical Coherence Tomography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (optical coherence tomography) used to monitor AMD treatment. | SAS | Posted | Number | participants | Every 6 weeks up to Week 102 |
|
|
|
| Other Pre-specified | Number of Participants for Whom Indocyanine Green Angiography Was Used to Monitor the Course of AMD Treatment | Participant counts by type of diagnostic procedure (indocyanine green angiography) used to monitor AMD treatment. | SAS | Posted | Number | participants | Every 6 weeks up to Week 102 |
|
|
|
| Other Pre-specified | Number of Participants Who Discontinued Treatment Prematurely or Changed Treatment During the Course of the Study | Participants with dose reduction or temporary discontinuation of treatment due to adverse events (AEs). | SAS | Posted | Number | participants | Baseline through Week 102 |
|
|
|
| Other Pre-specified | Change From Baseline to Final Visit in Intraocular Pressure (IOP) (Before and After Injection) | IOP was measured using either applanation or tonopen before intravitreal injection, reported as pre-dose and post-dose pressure. IOP valid range: 10-21 mmHg. Change: IOP at Visit X minus IOP at Baseline. | SAS; N=participants with evaluable data at baseline; n=participants with evaluable data at specified time point | Posted | Mean | Standard Deviation | millimeters of mercury (mmHg) | Baseline and Week 102 or ET | eyes | Participants |
|
|
|
| 1 |
| 85 |
| 5 |
| 85 |
| Uveitis | Eye disorders | MedDRA v14.1 | Non-systematic Assessment |
|
| Asthenia | General disorders | MedDRA v14.1 | Non-systematic Assessment |
|
| Systemic lupus erythematosus | Musculoskeletal and connective tissue disorders | MedDRA v14.1 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA v14.1 | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA v14.1 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Measurements |
|---|---|
|
| Change at Week 24 (n=43) |
|
| Change at Week 30 (n=37) |
|
| Change at Week 36 (n=31) |
|
| Change at Week 42 (n=28) |
|
| Change at Week 48 (n=25) |
|
| Change at Week 54 (n=23) |
|
| Change at Week 60 (n=19) |
|
| Change at Week 66 (n=13) |
|
| Change at Week 72 (n=10) |
|
| Change at Week 84 (n=8) |
|
| Change at Week 90 (n=4) |
|
| Change at Week 96 (n=2) |
|
| Change at Week 102 (n=2) |
|
| 0.0133 |
| 2-Sided |
| No |
| Superiority or Other |
| Change from baseline at Week 18 | paired t-test | 0.0278 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 24 | paired t-test | 0.0160 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 30 | paired t-test | 0.0264 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 36 | paired t-test | 0.0278 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 42 | paired t-test | 0.1854 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 48 | paired t-test | 0.1684 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 54 | paired t-test | 0.4718 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 60 | paired t-test | 0.4340 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 66 | paired t-test | 0.7765 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 72 | paired t-test | 0.7544 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 84 | paired t-test | 0.7201 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 90 | paired t-test | 0.5692 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 96 | paired t-test | 0.2749 | 2-Sided | No | Superiority or Other |
| Change from baseline at Week 102 | paired t-test | 0.2749 | 2-Sided | No | Superiority or Other |
| Title | Measurements |
|---|---|
|
| Change at Month 18 (n=4) |
|
| Change at Month 24 (n=2) |
|
| 0.1392 |
| 2-Sided |
| No |
| Superiority or Other |
| Change at Month 18 | paired t-test | 0.0573 | 2-Sided | No | Superiority or Other |
| Change at Month 24 | paired t-test | 0.7625 | 2-Sided | No | Superiority or Other |
|
| Near Activities, Change at Week 102/ET (n=59) |
|
| Distance Activities, Change at Week 102/ET (n=59) |
|
| Social Functioning, Change at Week 102/ET (n=59) |
|
| Mental Health, Change at Week 102/ET (n=59) |
|
| Role Difficulties, Change at Week 102/ET (n=59) |
|
| Dependency, Change at Week 102/ET (n=59) |
|
| Driving, Change at Week 102/ET (n=20) |
|
| Color Vision, Change at Week 102/ET (n=57) |
|
| Peripheral Vision, Change at Week 102/ET (n=59) |
|
|
| ≥ 65 years, Change at Week 102/ET (n=57) |
|
|
| Late Stage Lesion, Change at Week 102/ET (n=31) |
|
| Other AMD Stage, Baseline (n=1) |
|
| Other AMD Stage, Change at Week 102/ET (n=1) |
|
|
| Previous Treatment, Change at Week 102/ET (n=5) |
|
| Title | Measurements |
|---|
|
| Week 24 |
|
| Week 30 |
|
| Week 36 |
|
| Week 42 |
|
| Week 48 |
|
| Week 54 |
|
| Week 60 |
|
| Week 66 |
|
| Week 72 |
|
| Week 78 |
|
| Week 84 |
|
| Week 90 |
|
| Week 96 |
|
| Week 102 |
|
| Title | Measurements |
|---|
|
| Week 24 |
|
| Week 30 |
|
| Week 36 |
|
| Week 42 |
|
| Week 48 |
|
| Week 54 |
|
| Week 60 |
|
| Week 66 |
|
| Week 72 |
|
| Week 78 |
|
| Week 84 |
|
| Week 90 |
|
| Week 96 |
|
| Week 102 |
|
| Title | Measurements |
|---|
|
| Week 24 |
|
| Week 30 |
|
| Week 36 |
|
| Week 42 |
|
| Week 48 |
|
| Week 54 |
|
| Week 60 |
|
| Week 66 |
|
| Week 72 |
|
| Week 78 |
|
| Week 84 |
|
| Week 90 |
|
| Week 96 |
|
| Week 102 |
|
| Title | Measurements |
|---|---|
|